<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:15:33Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6913049" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6913049</identifier>
        <datestamp>2019-12-19</datestamp>
        <setSpec>ict</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Integr Cancer Ther</journal-id>
              <journal-id journal-id-type="iso-abbrev">Integr Cancer Ther</journal-id>
              <journal-id journal-id-type="publisher-id">ICT</journal-id>
              <journal-id journal-id-type="hwp">spict</journal-id>
              <journal-title-group>
                <journal-title>Integrative Cancer Therapies</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1534-7354</issn>
              <issn pub-type="epub">1552-695X</issn>
              <publisher>
                <publisher-name>SAGE Publications</publisher-name>
                <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6913049</article-id>
              <article-id pub-id-type="pmcid">PMC6913049</article-id>
              <article-id pub-id-type="pmc-uid">6913049</article-id>
              <article-id pub-id-type="pmid">31833799</article-id>
              <article-id pub-id-type="pmid">31833799</article-id>
              <article-id pub-id-type="doi">10.1177/1534735419893063</article-id>
              <article-id pub-id-type="publisher-id">10.1177_1534735419893063</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Cancer and the Microbiome</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Research Article</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ravilla</surname>
                    <given-names>Rahul</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff1-1534735419893063">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Coleman</surname>
                    <given-names>Hannah N.</given-names>
                  </name>
                  <degrees>BS</degrees>
                  <xref ref-type="aff" rid="aff1-1534735419893063">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chow</surname>
                    <given-names>Cheryl-Emiliane</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff2-1534735419893063">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chan</surname>
                    <given-names>Luisa</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff2-1534735419893063">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fuhrman</surname>
                    <given-names>Barbara J.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff1-1534735419893063">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Greenfield</surname>
                    <given-names>William W.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff1-1534735419893063">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7119-6301</contrib-id>
                  <name>
                    <surname>Robeson</surname>
                    <given-names>Michael Scott</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff1-1534735419893063">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Iverson</surname>
                    <given-names>Kathryn</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff2-1534735419893063">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Spencer</surname>
                    <given-names>Horace</given-names>
                    <suffix>III</suffix>
                  </name>
                  <degrees>MS</degrees>
                  <xref ref-type="aff" rid="aff1-1534735419893063">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0377-4613</contrib-id>
                  <name>
                    <surname>Nakagawa</surname>
                    <given-names>Mayumi</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff1-1534735419893063">1</xref>
                  <xref ref-type="corresp" rid="corresp1-1534735419893063"/>
                </contrib>
              </contrib-group>
              <aff id="aff1-1534735419893063"><label>1</label>University of Arkansas for Medical Sciences, Little Rock, AR, USA</aff>
              <aff id="aff2-1534735419893063"><label>2</label>Second Genome, Inc, South San Francisco, CA, USA</aff>
              <author-notes>
                <corresp id="corresp1-1534735419893063">Mayumi Nakagawa, Department of Pathology, College of Medicine, University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot 502, Little Rock, AR 72205, USA. Email: <email>mnakagawa@uams.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>13</day>
                <month>12</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2019</year>
              </pub-date>
              <volume>18</volume>
              <elocation-id>1534735419893063</elocation-id>
              <history>
                <date date-type="received">
                  <day>5</day>
                  <month>6</month>
                  <year>2019</year>
                </date>
                <date date-type="rev-recd">
                  <day>28</day>
                  <month>10</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>11</day>
                  <month>11</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2019</copyright-statement>
                <copyright-year>2019</copyright-year>
                <copyright-holder content-type="sage">SAGE Publications</copyright-holder>
                <license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
                  <license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
                </license>
              </permissions>
              <abstract>
                <p>Human papillomavirus (HPV) infection is associated with the vast majority of cervical cancer cases as well as with other anogenital cancers. PepCan is an investigational HPV therapeutic vaccine for treating cervical high-grade squamous intraepithelial lesions. The present study was performed to test whether the cervical microbiome influences vaccine responses and to explore host factors as determinants of the cervical microbiome composition in women with biopsy-proven high-grade squamous intraepithelial lesions. In a recently completed Phase I clinical trial of PepCan, histological response rate of 45% (14 of 31 patients), a significant increase in circulating T-helper type 1 cells, and a significant decrease in HPV 16 viral load were reported. DNA, extracted from liquid cytology specimens collected before and after vaccinations, were amplified and then hybridized to a G4 PhyloChip assay to characterize the microbiome. We describe trends that certain bacterial taxa in the cervix may be enriched in non-responders in comparison to responders (<italic>P</italic><sub>adj</sub> = .052 for phylum <italic>Caldithrix</italic> and <italic>P</italic><sub>adj</sub> = .059 for phylum <italic>Nitrospirae</italic>). There was no difference in bacterial diversity between the 2 groups. A permutational analysis of variance performed for various demographic and immune parameters showed significant clustering with microbiome beta diversity for race, HPV 16 status, peripheral T-helper type 1 cells, and HLA-B40 (<italic>P</italic> = .001, .014, .037, and .024, respectively). Further analyses showed significant differences at the empirical Operational Taxonomic Unit level for race and HPV 16 status. As these results are from a small Phase I study, further studies are needed to examine the role of cervical microbiome in response to HPV therapeutic vaccines.</p>
              </abstract>
              <kwd-group>
                <kwd>cervical microbiome</kwd>
                <kwd>therapeutic vaccine</kwd>
                <kwd>cervical cancer</kwd>
                <kwd>high-grade squamous intraepithelial lesions</kwd>
                <kwd>human papillomavirus</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="award1-1534735419893063">
                  <funding-source id="funding1-1534735419893063">
                    <institution-wrap>
                      <institution>National Institutes of Health</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000002</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id rid="funding1-1534735419893063">R01 CA143130</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>January-December 2019</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>typesetter</meta-name>
                  <meta-value>ts1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="section1-1534735419893063">
              <title>Introduction</title>
              <p>High-risk human papillomaviruses (HPVs) are best known as the causative agent of cervical cancer, but they are also associated with other cancers of mucous membranes such as anal, oropharyngeal, penile, vaginal, and vulvar cancers.<sup><xref rid="bibr1-1534735419893063" ref-type="bibr">1</xref></sup> Among the high-risk HPV types, HPV type 16 (HPV 16) is the most dominant in terms of the number of cancer cases.</p>
              <p>An immune-based therapy for cervical precancers are needed, as the current standard of care surgical treatments are known to result in doubling of preterm deliveries in future pregnancies.<sup><xref rid="bibr2-1534735419893063" ref-type="bibr">2</xref></sup> PepCan is an investigational HPV therapeutic vaccine, which consists of 4 current Good Manufacturing Practice synthetic peptides covering the HPV 16 E6 protein amino acid sequence and a <italic>Candida</italic> skin test reagent as a vaccine adjuvant to enhance immune response.<sup><xref rid="bibr3-1534735419893063" ref-type="bibr">3</xref>,<xref rid="bibr4-1534735419893063" ref-type="bibr">4</xref></sup> In this Phase 1 dose-escalation clinical trial, 34 women with biopsy-proven high-grade squamous intraepithelial lesions (HSILs) were given 4 intradermal injections of PepCan 3 weeks apart. Three months after the last injection, loop electrical excision procedure (LEEP) was performed as a standard of care treatment and to categorize recipients into responders (n = 14) and nonresponders (n = 17). Three subjects did not complete the study. We previously reported that the vaccine was safe,<sup><xref rid="bibr3-1534735419893063" ref-type="bibr">3</xref>,<xref rid="bibr4-1534735419893063" ref-type="bibr">4</xref></sup> can significantly decrease HPV 16 viral load,<sup><xref rid="bibr3-1534735419893063" ref-type="bibr">3</xref></sup> and can significantly increase circulating T-helper type 1 (Th1) cells.<sup><xref rid="bibr3-1534735419893063" ref-type="bibr">3</xref>,<xref rid="bibr4-1534735419893063" ref-type="bibr">4</xref></sup></p>
              <p>Multiple studies have reported that antitumor response with checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or PD-1 ligand is modulated by the composition of gut microbiota.<sup><xref rid="bibr5-1534735419893063" ref-type="bibr">5</xref><xref rid="bibr6-1534735419893063" ref-type="bibr"/><xref rid="bibr7-1534735419893063" ref-type="bibr"/><xref rid="bibr8-1534735419893063" ref-type="bibr"/><xref rid="bibr9-1534735419893063" ref-type="bibr"/>-<xref rid="bibr10-1534735419893063" ref-type="bibr">10</xref></sup> The use of broad-spectrum antibiotics resulting in disruption of healthy microbiota could be related to the failure of such immunotherapy.<sup><xref rid="bibr7-1534735419893063" ref-type="bibr">7</xref></sup> Furthermore, different bacterial taxa that positively correlate with good clinical responses were described in studies examining differing patient populations.<sup><xref rid="bibr5-1534735419893063" ref-type="bibr">5</xref><xref rid="bibr6-1534735419893063" ref-type="bibr"/><xref rid="bibr7-1534735419893063" ref-type="bibr"/><xref rid="bibr8-1534735419893063" ref-type="bibr"/><xref rid="bibr9-1534735419893063" ref-type="bibr"/>-<xref rid="bibr10-1534735419893063" ref-type="bibr">10</xref></sup> For example, Gopalakrishnan et al<sup><xref rid="bibr5-1534735419893063" ref-type="bibr">5</xref></sup> reported significantly higher alpha diversity and relative abundance of the <italic>Ruminococcaceae</italic> family in melanoma patients responding to the anti-PD-1 immunotherapy.<sup><xref rid="bibr5-1534735419893063" ref-type="bibr">5</xref></sup> While the role of gut microbiome has been studied robustly, the microbiome of the disease site (eg, skin for melanoma patients) has not received as much attention and has not been investigated.<sup><xref rid="bibr5-1534735419893063" ref-type="bibr">5</xref></sup> We intended to fill this gap by examining the cervical microbiome of women being treated for HSILs using our investigational therapeutic vaccine, PepCan.</p>
              <p>HPV infection has been shown to influence the microbiome composition in the cervicovaginal milieu,<sup><xref rid="bibr11-1534735419893063" ref-type="bibr">11</xref><xref rid="bibr12-1534735419893063" ref-type="bibr"/><xref rid="bibr13-1534735419893063" ref-type="bibr"/>-<xref rid="bibr14-1534735419893063" ref-type="bibr">14</xref></sup> and differing abundance of <italic>Lactobacillus</italic> species has been reported based on race.<sup><xref rid="bibr15-1534735419893063" ref-type="bibr">15</xref>,<xref rid="bibr16-1534735419893063" ref-type="bibr">16</xref></sup> Therefore, we examined not only the role of cervical microbiome in relation to HPV therapeutic vaccine response in this study, but also explored whether various demographic/immune parameters and the HPV status may influence the cervical microbiome composition.</p>
            </sec>
            <sec sec-type="methods" id="section2-1534735419893063">
              <title>Methods</title>
              <sec id="section3-1534735419893063">
                <title>Patients</title>
                <p>The patients whose cervical samples were studied were all participants of a Phase I clinical trial of an HPV therapeutic vaccine, PepCan, which has been reported previously.<sup><xref rid="bibr3-1534735419893063" ref-type="bibr">3</xref>,<xref rid="bibr4-1534735419893063" ref-type="bibr">4</xref></sup> Written informed consent was obtained from all participants. The vaccine contains 4 current Good Manufacturing Practice–grade synthetic peptides covering the HPV 16 E6 protein and Candin (Allermed, San Diego, CA), a colorless extract of <italic>Candida albicans</italic>, as a vaccine adjuvant.<sup><xref rid="bibr17-1534735419893063" ref-type="bibr">17</xref></sup> This was a single-center, single-arm, dose-escalation, Phase I clinical trial (NCT00569231). Women with biopsy-proven HSILs were eligible for intradermal vaccination, which was administered in limbs (most commonly administered in forearms, and less commonly in the outer thigh) every 3 weeks for a total of 4 injections. The doses of the peptides tested were 50 µg/peptide, 100 µg/peptide, 250 µg/peptide, and 500 µg/peptide, and 6 patients were tested in each dose group. Each patient received the same peptide dose for all 4 injections. The amount of Candin, 0.3 mL, was held constant at the dose successfully used to treat common warts.<sup><xref rid="bibr18-1534735419893063" ref-type="bibr">18</xref></sup> After completing the dose escalation phase, 10 additional patients were vaccinated at the 50 µg/peptide dose, which was shown to be optimal in terms of histological regression and HPV clearance.<sup><xref rid="bibr3-1534735419893063" ref-type="bibr">3</xref>,<xref rid="bibr4-1534735419893063" ref-type="bibr">4</xref></sup> Twelve weeks after the last vaccination, LEEP was performed. Although the goal of developing HPV therapeutic vaccines is to replace an excisional procedure such as LEEP, it was performed since the primary objective of the Phase I study was to assess safety. Furthermore, histological response to the vaccine could be assessed by examining the LEEP biopsies. Subjects with persistent HSIL were considered to be vaccine nonresponders while those without HSIL (complete) and those with HSIL measuring ≤0.2 mm<sup>2</sup> (partial) were considered to be responders. Forkhead box P3 (FOXP3) staining of LEEP sample was performed to quantify regulatory T-cell (T<sub>reg</sub>) levels in the epithelium of cervical intraepithelial lesions and their corresponding stroma. Blood was drawn once before and twice after vaccination started (<xref ref-type="fig" rid="fig1-1534735419893063">Figure 1</xref>), and was used to perform HLA typing (One Lambda, Canoga Park, CA), and immune profiling of circulating Th1 cells, T-helper type 2 (Th2) cells, and T<sub>regs</sub>. A histological regression rate nearly double of a historical placebo group from another clinical trial of HPV therapeutic vaccine, and a significant decrease in HPV 16 viral load were observed.<sup><xref rid="bibr3-1534735419893063" ref-type="bibr">3</xref>,<xref rid="bibr4-1534735419893063" ref-type="bibr">4</xref></sup></p>
                <fig id="fig1-1534735419893063" orientation="portrait" position="float">
                  <label>Figure 1.</label>
                  <caption>
                    <p>Study scheme showing that the initial cervical sample was taken prior to 4 vaccinations given 3 weeks apart in women with biopsy-proven high-grade squamous intraepithelial lesions (HSILs). Three months after the last vaccination, a repeat cervical sample was taken immediately prior to having loop electrical excision procedure (LEEP) performed based on which responders and nonresponders were described.</p>
                  </caption>
                  <graphic xlink:href="10.1177_1534735419893063-fig1"/>
                </fig>
              </sec>
              <sec id="section4-1534735419893063">
                <title>Collection of Cervical Cells and Processing</title>
                <p>ThinPrep (Hologic, Marlborough, MA) was used to collect cervical cells at the screening visit (before vaccination) and at the exit visit (after vaccination). Three patients exited the study early for personal reasons, and therefore provided only prevaccination cervical samples. The central part of the broom-like device was inserted into the endocervix and rotated 360° to collect cells from the endocervix and the entire ectocervix. In addition, a cervical brush was used to collect more cells from the endocervix. Cells were equally distributed by vortexing and were stored at −80°C. DNA was isolated using the Qiagen QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) as per manufacturer instructions. DNA was quantified using ND-1000 NanoDrop (NanoDrop Technologies, Wilmington, DE), and was used for HPV testing (Linear Array HPV Genotyping Test, Roche Molecular Diagnostics, Pleasanton, CA), HPV 16 viral load determination,<sup><xref rid="bibr3-1534735419893063" ref-type="bibr">3</xref></sup> and microbiome analysis as described below.</p>
              </sec>
              <sec id="section5-1534735419893063">
                <title>Polymerase Chain Reaction Amplification and Hybridization</title>
                <p>DNA was amplified by polymerase chain reaction (PCR; 30 cycles in duplicate) with a bacterial 16S rRNA gene degenerate forward primer (27F.1 5′-AGRGTTTGATCMTGGCTCAG-3′) and a nondegenerate reverse primer, 1492R.jgi (5′-GGTTACCTTGTTACGACTT-3′). Amplified products from each sample were concentrated with a solid-phase reversible immobilization method and quantified with an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc, Santa Clara, CA). PhyloChip Control Mix was added to 500 ng of PCR products from each sample. Assuming an average GC content of 54% (Greengenes database of 16S rRNA genes)<sup><xref rid="bibr19-1534735419893063" ref-type="bibr">19</xref></sup> and an amplicon length of 1465 bp, 3.3 × 10<sup>11</sup> molecules were assayed from each sample.<sup><xref rid="bibr20-1534735419893063" ref-type="bibr">20</xref></sup> The amplicons were then fragmented, labeled with biotin, and hybridized to the PhyloChip Array (version G4).<sup><xref rid="bibr21-1534735419893063" ref-type="bibr">21</xref></sup></p>
                <p>The arrays were washed, stained, and scanned using a GeneTitan scanner (ThermoFisher Scientific, Waltham, MA). Standard Affymetrix software (GeneChip Microarray Analysis Suite, ThermoFisher Scientific) was used to capture the scans. Only perfect-match probes with fluorescence intensity observed in at least 4 samples (n = 1111) were exported for rank-normalization in Sinfonietta software (Second Genome, Inc, South San Francisco, CA), and were used as input to empirical probe-set discovery. All probe sets contained 5 or more probes, and the empirical Operational Taxonomic Units (eOTU) tracked by a probe set were taxonomically annotated against the May 2013 release of Greengenes database.<sup><xref rid="bibr22-1534735419893063" ref-type="bibr">22</xref></sup> Where standard taxonomic names have not been established, hierarchical taxon identifiers were used. Analyses were conducted on hybridization scores (HybScores), which are the mean normalized rank for all probes within an eOTU. The probes were ranked according to their scaled-background subtracted fluorescence intensities.</p>
              </sec>
              <sec id="section6-1534735419893063">
                <title>Statistical Analyses</title>
                <p>Alpha diversity refers to the richness of individual cervical samples. It was calculated as a sum of unique eOTUs found in each sample, using the Phylogenetic Diversity.<sup><xref rid="bibr23-1534735419893063" ref-type="bibr">23</xref><xref rid="bibr24-1534735419893063" ref-type="bibr"/>-<xref rid="bibr25-1534735419893063" ref-type="bibr">25</xref></sup> In contrast, beta diversity was defined by intersample comparisons performed in a pairwise fashion. Beta diversity was expressed as a dissimilarity score and was stored in a distance dissimilarity matrix. Abundance-weighted sample pairwise differences were calculated using the Bray-Curtis dissimilarity.<sup><xref rid="bibr26-1534735419893063" ref-type="bibr">26</xref></sup> The binary dissimilarity values were calculated with the Jaccard index.<sup><xref rid="bibr27-1534735419893063" ref-type="bibr">27</xref></sup> Principal coordinate analysis was performed in which 2-dimensional ordinations were created to graphically summarize the inter-sample relationships. Permutational analysis of variance<sup><xref rid="bibr28-1534735419893063" ref-type="bibr">28</xref></sup> was used to identify significant differences in the microbiome at the eOTU level in concordance with discrete categorical variable or in association with continuous variables. Fast Unifrac was applied to identify well-defined subcategories using the Biotype R package.<sup><xref rid="bibr29-1534735419893063" ref-type="bibr">29</xref>,<xref rid="bibr30-1534735419893063" ref-type="bibr">30</xref></sup> The difference between the 2 biotypes with regard to HPV 16 status or race was calculated using Fisher’s exact test. The difference in representation of 20 families between biotypes 1 and 2 were calculated using the Wilcoxon rank sum test followed by a Benjamini-Hochberg correction. We limited the analyses of HLA types to those previously shown to be associated with HSIL compared with the general population in the United States, and those detected in at least 5 study participants.<sup><xref rid="bibr3-1534735419893063" ref-type="bibr">3</xref>,<xref rid="bibr4-1534735419893063" ref-type="bibr">4</xref></sup></p>
                <p>Differentially abundant phyla, families, genera, and eOTUs were identified using a Welch <italic>t</italic> test. Where samples could be paired across categories, a paired Welch <italic>t</italic> test was performed. <italic>P</italic> values were adjusted by Benjamini-Hochberg procedures to control for multiple testing<sup><xref rid="bibr31-1534735419893063" ref-type="bibr">31</xref></sup> for eOTU abundance testing.</p>
                <p>For covariates which had <italic>P</italic> values less than .05, the differences were further analyzed for 1111 eOTUs selected as described above. Quantile normalization was applied to raw hybridization intensity scores. Then, a generalized linear model was applied to each eOTU to assess the comparison of interest (eg, Caucasian vs non-Caucasian, HPV 16-positive vs HPV 16-negative, percent peripheral Th1 cells, and HLA-B40-positive vs B40-negative), and a Benjamini-Hochberg correction was applied to adjust for multiple comparisons.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="section7-1534735419893063">
              <title>Results</title>
              <p>Of 31 subjects who received vaccinations and completed the study (<xref ref-type="fig" rid="fig1-1534735419893063">Figure 1</xref>), 14 (45%) were responders and 17 (55%) were nonresponders as determined by the histological findings in LEEP.<sup><xref rid="bibr3-1534735419893063" ref-type="bibr">3</xref>,<xref rid="bibr4-1534735419893063" ref-type="bibr">4</xref></sup> There were no significant differences between these 2 groups with regard to age, histological finding at entry, race, and HPV status at entry (<xref rid="table1-1534735419893063" ref-type="table">Table 1</xref>). Alpha diversity eOTU richness ranged from 72 to 365 (mean = 232) eOTUs per sample. In all, 2 unique kingdoms, 46 phyla, 108 classes, 184 orders, 285 families, 414 genera, 586 species, and 1111 eOTUs were detected. The 10 most abundant phyla were <italic>Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Tenericutes, Planctomycetes, Cyanobacteria, Euryarchaeota, Chloroflexi</italic>, and <italic>Acidobacteria</italic> (<xref ref-type="fig" rid="fig2-1534735419893063">Figure 2A</xref>). The 10 most abundant families were <italic>Prevotellaceae, Lactobacillaceae, Lachnospiraceae, Streptococcaceae, Mycoplasmataceae, Bacillaceae, Enterobacteriaceae, Spirochaetacea, Veillonellaceae</italic>, and <italic>Pasteurellaceae</italic> (<xref ref-type="fig" rid="fig2-1534735419893063">Figure 2B</xref>).</p>
              <table-wrap id="table1-1534735419893063" orientation="portrait" position="float">
                <label>Table 1.</label>
                <caption>
                  <p>Baseline Characteristics of Patients<sup><xref ref-type="table-fn" rid="table-fn2-1534735419893063">a</xref></sup>.</p>
                </caption>
                <alternatives>
                  <graphic xlink:href="10.1177_1534735419893063-table1"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="center" rowspan="1" colspan="1">Characteristics</th>
                        <th align="center" rowspan="1" colspan="1">Responders (N = 14)</th>
                        <th align="center" rowspan="1" colspan="1">Nonresponders (N = 17)</th>
                        <th align="center" rowspan="1" colspan="1">
                          <italic>P</italic>
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td colspan="4" rowspan="1">Age (years)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Mean ± SD</td>
                        <td rowspan="1" colspan="1">31.3 ± 8.3</td>
                        <td rowspan="1" colspan="1">29.5 ± 4.6</td>
                        <td rowspan="1" colspan="1">.4632</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Range</td>
                        <td rowspan="1" colspan="1">22-49</td>
                        <td rowspan="1" colspan="1">22-37</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td colspan="4" rowspan="1">Histology at entry, n (%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> CIN2</td>
                        <td rowspan="1" colspan="1">6 (42.9%)</td>
                        <td rowspan="1" colspan="1">6 (35.3%)</td>
                        <td rowspan="1" colspan="1">.9524</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> CIN3</td>
                        <td rowspan="1" colspan="1">8 (57.1%)</td>
                        <td rowspan="1" colspan="1">11 (64.7%)</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td colspan="4" rowspan="1">Race, n (%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Caucasian</td>
                        <td rowspan="1" colspan="1">7 (50.0%)</td>
                        <td rowspan="1" colspan="1">5 (29.4%)</td>
                        <td rowspan="1" colspan="1">.4233</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> African American</td>
                        <td rowspan="1" colspan="1">6 (42.9%)</td>
                        <td rowspan="1" colspan="1">12 (70.6%)</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Other</td>
                        <td rowspan="1" colspan="1">1 (7.1%)</td>
                        <td align="center" rowspan="1" colspan="1">—</td>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td colspan="4" rowspan="1">HPV 16 status at entry, n (%)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Positive</td>
                        <td rowspan="1" colspan="1">5 (35.7%)</td>
                        <td rowspan="1" colspan="1">7 (41.2%)</td>
                        <td rowspan="1" colspan="1">&gt;.99</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="table-fn1-1534735419893063">
                    <p>Abbreviations: HPV, human papillomavirus; SD, standard deviation.</p>
                  </fn>
                  <fn id="table-fn2-1534735419893063">
                    <label>a</label>
                    <p>A 2-sample <italic>t</italic> test was used to assess age and Pearson’s χ<sup>2</sup> tests were used to assess histology, race, and HPV status.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <fig id="fig2-1534735419893063" orientation="portrait" position="float">
                <label>Figure 2.</label>
                <caption>
                  <p>Stacked bar plot of phylogenetic composition of the 10 most common bacterial taxa at (A) the phylum and (B) family levels based on relative HybScores in cervical ThinPrep samples collected at the screening visits (prevaccination) and the exit visits (after 4 vaccinations).</p>
                </caption>
                <graphic xlink:href="10.1177_1534735419893063-fig2"/>
              </fig>
              <p>Among the 46 phyla examined, <italic>Caldithrix</italic> and <italic>Nitrospirae</italic> appeared to be enriched in nonresponders, approaching statistical significance after correction for multiple analyses (<xref ref-type="fig" rid="fig3-1534735419893063">Figure 3</xref>; <italic>P</italic><sub>adj</sub> = .052 and .059, respectively). Three of the 1111 eOTUs observed in this study were enriched in the nonresponder group compared with the vaccine response group (at <italic>P</italic> &lt; .05; <xref ref-type="fig" rid="fig4-1534735419893063">Figure 4</xref>): <italic>Prevotella</italic> sp (<italic>Prevotellaceae</italic>), A17 sp (family <italic>Pirellulaceae</italic>), and an unclassified species (94otu38814) in the family <italic>Sphingomonadaceae</italic>. No significant differences were found between cervical microbiome diversity before and after vaccination with regard to alpha diversity, phyla (n = 46), families (n = 285), and eOTUs (n = 1111). There was no difference in alpha diversity between the 2 groups.</p>
              <fig id="fig3-1534735419893063" orientation="portrait" position="float">
                <label>Figure 3.</label>
                <caption>
                  <p>Phyla (<italic>Caldithrix</italic> and <italic>Nitrospirae</italic>) differing between vaccine nonresponders (green) and responders (blue) approaching statistical significance after adjustment for multiple comparisons (<italic>P</italic><sub>adj</sub> = .052 and .059, respectively). HybScores were added for all eOTUs within each phylum.</p>
                </caption>
                <graphic xlink:href="10.1177_1534735419893063-fig3"/>
              </fig>
              <fig id="fig4-1534735419893063" orientation="portrait" position="float">
                <label>Figure 4.</label>
                <caption>
                  <p>Three eOTUs with <italic>P</italic> &lt; .05 were enriched in the vaccine non-responder group including <italic>Prevotella</italic> sp (<italic>Prevotellaceae</italic>), A17 sp (family <italic>Pirellulaceae</italic>), and an unclassified species (94otu38814) in the family <italic>Sphingomonadaceae</italic>.</p>
                </caption>
                <graphic xlink:href="10.1177_1534735419893063-fig4"/>
              </fig>
              <p>A permutational analysis of variance using distance matrices was performed for each variable of interest to determine if there was significant clustering with regard to the beta diversity of the samples (<xref rid="table2-1534735419893063" ref-type="table">Table 2</xref>). <italic>P</italic> values of &lt;.05 were found for race (<xref ref-type="fig" rid="fig5-1534735419893063">Figure 5A</xref>), HPV 16 status (<xref ref-type="fig" rid="fig5-1534735419893063">Figure 5B</xref>), peripheral Th1 cells, and HLA B40 or not. When these variables were further analyzed at the eOTU level, significant differences were found in 498 eOTUs with regard to race, and in 15 eOTUs with regard to HPV 16-positivity after adjusting for multiple comparisons (<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1534735419893063">Supplementary Tables 1 and 2</ext-link>; available online).</p>
              <table-wrap id="table2-1534735419893063" orientation="portrait" position="float">
                <label>Table 2.</label>
                <caption>
                  <p>Clustering Between Subject Characteristics and Variations in Cervical Bacterial Composition.</p>
                </caption>
                <alternatives>
                  <graphic xlink:href="10.1177_1534735419893063-table2"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="center" rowspan="1" colspan="1">Variables</th>
                        <th align="center" rowspan="1" colspan="1">
                          <italic>P</italic>
                        </th>
                        <th align="center" rowspan="1" colspan="1">Classes or Range</th>
                        <th align="center" rowspan="1" colspan="1">Sample Count</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Age</td>
                        <td rowspan="1" colspan="1">.147</td>
                        <td rowspan="1" colspan="1">22.3 to 49.5 years old</td>
                        <td rowspan="1" colspan="1">34</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Race</td>
                        <td rowspan="1" colspan="1">
                          <bold>.001</bold>
                        </td>
                        <td rowspan="1" colspan="1">African American, Caucasian, and Hispanic</td>
                        <td rowspan="1" colspan="1">21, 12, 1</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Histological response</td>
                        <td rowspan="1" colspan="1">.34</td>
                        <td rowspan="1" colspan="1">Responder and nonresponder</td>
                        <td rowspan="1" colspan="1">14, 17</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">HPV clearance</td>
                        <td rowspan="1" colspan="1">.554</td>
                        <td rowspan="1" colspan="1">Cleared at least one HPV type, no</td>
                        <td rowspan="1" colspan="1">19, 12</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Peripheral Treg</td>
                        <td rowspan="1" colspan="1">.228</td>
                        <td rowspan="1" colspan="1">0.1% to 2.4% CD4 cells</td>
                        <td rowspan="1" colspan="1">29</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Peripheral Th1</td>
                        <td rowspan="1" colspan="1">
                          <bold>.037</bold>
                        </td>
                        <td rowspan="1" colspan="1">2.6% to 40.2% CD4 cells</td>
                        <td rowspan="1" colspan="1">29</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Peripheral Th2</td>
                        <td rowspan="1" colspan="1">.846</td>
                        <td rowspan="1" colspan="1">15.5% to 94.6% CD4 cells</td>
                        <td rowspan="1" colspan="1">28</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">HLA B15</td>
                        <td rowspan="1" colspan="1">.191</td>
                        <td rowspan="1" colspan="1">B15 positive, B15 negative</td>
                        <td rowspan="1" colspan="1">7, 27</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">HLA B40</td>
                        <td rowspan="1" colspan="1">
                          <bold>.024</bold>
                        </td>
                        <td rowspan="1" colspan="1">B40 positive, B40 negative</td>
                        <td rowspan="1" colspan="1">5, 29</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">HLA C3</td>
                        <td rowspan="1" colspan="1">.488</td>
                        <td rowspan="1" colspan="1">C3 positive, C3 negative</td>
                        <td rowspan="1" colspan="1">9, 25</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">HLA DQ3</td>
                        <td rowspan="1" colspan="1">.371</td>
                        <td rowspan="1" colspan="1">DQ3 positive, DQ3 negative</td>
                        <td rowspan="1" colspan="1">19, 15</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Cervical Treg in epithelium<sup><xref ref-type="table-fn" rid="table-fn5-1534735419893063">1</xref></sup></td>
                        <td rowspan="1" colspan="1">.996</td>
                        <td rowspan="1" colspan="1">3 to 800 cells/mm<sup>2</sup></td>
                        <td rowspan="1" colspan="1">30</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Cervical Treg in stroma<sup><xref ref-type="table-fn" rid="table-fn5-1534735419893063">1</xref></sup></td>
                        <td rowspan="1" colspan="1">.385</td>
                        <td rowspan="1" colspan="1">13 to 2240 cells/mm<sup>2</sup></td>
                        <td rowspan="1" colspan="1">30</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Dose<sup><xref ref-type="table-fn" rid="table-fn5-1534735419893063">1</xref></sup></td>
                        <td rowspan="1" colspan="1">.633</td>
                        <td rowspan="1" colspan="1">50 µg, 100 µg, 250 µg, and 500 µg</td>
                        <td rowspan="1" colspan="1">14, 6, 6, 5</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">HPV 16 or not<sup><xref ref-type="table-fn" rid="table-fn5-1534735419893063">2</xref></sup></td>
                        <td rowspan="1" colspan="1">
                          <bold>.014</bold>
                        </td>
                        <td rowspan="1" colspan="1">HPV 16 positive, HPV 16 negative</td>
                        <td rowspan="1" colspan="1">22, 43</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Vaccination<sup><xref ref-type="table-fn" rid="table-fn5-1534735419893063">2</xref></sup></td>
                        <td rowspan="1" colspan="1">.375</td>
                        <td rowspan="1" colspan="1">Pre-vaccination, post-vaccination</td>
                        <td rowspan="1" colspan="1">34, 31</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="table-fn3-1534735419893063">
                    <p>Abbreviations: HPV, human papillomavirus; Th, T-helper type; HLA, human leukocyte antigen.</p>
                  </fn>
                  <fn id="table-fn4-1534735419893063">
                    <p>A permutational analysis of variance using distance matrices was performed for each variable of interest to determine if it significantly contributed to the beta diversity of the samples.</p>
                  </fn>
                  <fn id="table-fn5-1534735419893063">
                    <p>Baseline characteristics and cervical samples were examined for all variables with these exceptions: <sup>1</sup>Samples from the exit visits were examined for “cervical Treg in epithelium,” “cervical Treg in stroma,” and “dose” and <sup>2</sup>both samples were included for “HPV 16 or not” and “vaccination.”</p>
                  </fn>
                  <fn id="table-fn6-1534735419893063">
                    <p>Bold values indicate <italic>P</italic> &lt; .05.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <fig id="fig5-1534735419893063" orientation="portrait" position="float">
                <label>Figure 5.</label>
                <caption>
                  <p>Significant associations with microbiome beta diversity were shown for race (<italic>P</italic> = .001) and human papillomavirus 16 (HPV 16) positivity (<italic>P</italic> = .014). Dimensional reductions of the Bray-Curtis dissimilarity between microbiome samples, using the principal coordinate analysis (PCoA) ordination method are shown for (A) race (Caucasian [blue], African American [green], and Hispanic [magenta]) prior to vaccination, and for (B) HPV 16 positivity (HPV 16-positive [green] and HPV 16-negative [blue]) for all samples.</p>
                </caption>
                <graphic xlink:href="10.1177_1534735419893063-fig5"/>
              </fig>
              <p>When Fast Unifrac was applied to identify subcategories analogous to community state types, 2 distinct biotypes were elucidated (<xref ref-type="fig" rid="fig6-1534735419893063">Figure 6A</xref>). The biotype 1 and biotype 2 differed significantly based on HPV 16 status (<italic>P</italic> = .0088) and race (Caucasian vs non-Caucasian, <italic>P</italic> = .0021). The families significantly over-represented in biotype 1 were <italic>Enterococcaceae, Mycoplasmataceae, Bacillaceae, Pasteurellaceae, Clostridiaceae, Phycisphaeraceae, Staphylococcaceae, Corynebacteriaceae, Lactobacillaceae, Pirellulaceae, Streptococcaceae</italic>, and <italic>Enterobactericeae</italic>, and those underrepresented were <italic>Prevotellaceae, Lachnospiraceae, Micrococcaceae, Porphyromonadaceae</italic>, and <italic>Veillonellaceae</italic> (<xref ref-type="fig" rid="fig6-1534735419893063">Figure 6B</xref>).</p>
              <fig id="fig6-1534735419893063" orientation="portrait" position="float">
                <label>Figure 6.</label>
                <caption>
                  <p>Fast UniFrac analysis revealing biotype 1 and biotype 2, which differ significantly based on human papillomavirus 16 (HPV 16) status (<italic>P</italic> = .0088) and race (<italic>P</italic> = .0021). (A) A heat map showing individual samples with regard to race, time point, and HPV 16 status. Each line represents eOTU and it abundance based on HybScore. (B) Box plots showing representation of 20 families between biotypes 1 and 2.</p>
                </caption>
                <graphic xlink:href="10.1177_1534735419893063-fig6"/>
              </fig>
            </sec>
            <sec sec-type="discussion" id="section8-1534735419893063">
              <title>Discussion</title>
              <p>To our knowledge, this study of women with HSILs was the first to examine the effects of the cervical microbiome in response to therapeutic HPV vaccination. This is of clinical interest since others have shown the impact of the gut microbiome on patient’s responses to checkpoint inhibitors,<sup><xref rid="bibr5-1534735419893063" ref-type="bibr">5</xref><xref rid="bibr6-1534735419893063" ref-type="bibr"/><xref rid="bibr7-1534735419893063" ref-type="bibr"/><xref rid="bibr8-1534735419893063" ref-type="bibr"/><xref rid="bibr9-1534735419893063" ref-type="bibr"/>-<xref rid="bibr10-1534735419893063" ref-type="bibr">10</xref></sup> but not necessarily that of a local microbiome, for example, that of the skin in melanoma patients. We studied the cervical microbiome in patients with biopsy-proven HSILs prior to receiving an investigational HPV therapeutic vaccine, and have described trends of phyla <italic>Caldithrix</italic> and <italic>Nitrospirae</italic> being enriched in the nonresponder group (<xref ref-type="fig" rid="fig3-1534735419893063">Figure 3</xref>; <italic>P</italic><sub>adj</sub> = .052 and .059, respectively). Furthermore, 3 eOTUs were enriched in the vaccine nonresponder group, including <italic>Prevotella</italic> sp (<italic>Prevotellaceae</italic>), A17 sp (family <italic>Pirellulaceae</italic>), and an unclassified species (94otu38814) in the family <italic>Sphingomonadaceae</italic> (<xref ref-type="fig" rid="fig4-1534735419893063">Figure 4</xref>). Therefore, a local microbiome could potentially influence the mounting of immune response to consequences of local disease (ie, HSIL).</p>
              <p>Huang et al<sup><xref rid="bibr32-1534735419893063" ref-type="bibr">32</xref></sup> conducted a study comparing the cervicovaginal community profiles among the cervix, posterior fornix, and vaginal canal of nonpregnant women, women in different stages of pregnancy, and postpartum women. Based on their results, it has been proposed that the cervicovaginal microbial communities were homogenous across these 3 anatomic sites although there was a substantial person-to-person variation.<sup><xref rid="bibr32-1534735419893063" ref-type="bibr">32</xref></sup></p>
              <p>Our data presented above showed overabundance of <italic>Caldithrix, Nirtospirae, Prevotella</italic> sp A17 sp (family <italic>Pirellulaceae</italic>), and an unclassified species (94otu38814) in vaccine nonresponders, suggesting that certain bacterial taxa may influence immunological responses to vaccination. <italic>Prevotella</italic> has been best characterized as having a role in gynecological and general health.<sup><xref rid="bibr33-1534735419893063" ref-type="bibr">33</xref>,<xref rid="bibr34-1534735419893063" ref-type="bibr">34</xref></sup>
<italic>Prevotella</italic> has been shown to be the key vaginal microbial species influencing host menopause, bacterial vaginosis, cervicitis, HPV status, body mass index, and hormone therapy.<sup><xref rid="bibr34-1534735419893063" ref-type="bibr">34</xref>,<xref rid="bibr35-1534735419893063" ref-type="bibr">35</xref></sup> Therefore, it is possible that the abundance of <italic>Prevotella</italic> may be creating an environment conducive for HPV infection to take hold, thereby dampening the effect of therapeutic vaccination. The potential mechanisms for <italic>Caldithrix</italic> and <italic>Nitrospirae</italic> are difficult to speculate, as <italic>Caldithrix</italic> has been reported to be a nitrate-reducing, thermophilic, anaerobic bacterium<sup><xref rid="bibr36-1534735419893063" ref-type="bibr">36</xref></sup> and <italic>Nitrospirae</italic> has been shown to alleviate nitrite toxicity by converting nitrite into nitrate in aquatic organisms.<sup><xref rid="bibr37-1534735419893063" ref-type="bibr">37</xref></sup> As classification of bacterial taxa is a dynamic process, it is possible that organisms identified in this study are closely related, but are of distinct taxa.</p>
              <p>We found no difference in alpha diversity of cervical microbiome between responders and nonresponders prior to vaccination. This is in contrast to other studies of gut microbiome, which showed that higher alpha diversity is associated with better response to anti-PD-1 immunotherapy.<sup><xref rid="bibr5-1534735419893063" ref-type="bibr">5</xref>,<xref rid="bibr8-1534735419893063" ref-type="bibr">8</xref><xref rid="bibr9-1534735419893063" ref-type="bibr"/>-<xref rid="bibr10-1534735419893063" ref-type="bibr">10</xref></sup> Use of antibiotics has also been shown to be associated with reduced response to anti-PD-1 immunotherapy,<sup><xref rid="bibr7-1534735419893063" ref-type="bibr">7</xref></sup> suggesting a positive role of a healthy, diverse gut microbiome. Such a difference between the state of cervical and gut microbiomes in association with immune-based therapy may be a reflection of the difference in the baseline healthy states of these microbiota. More diverse gut microbiota are known to be associated with better response to immune checkpoint inhibitor therapy,<sup><xref rid="bibr5-1534735419893063" ref-type="bibr">5</xref>,<xref rid="bibr8-1534735419893063" ref-type="bibr">8</xref><xref rid="bibr9-1534735419893063" ref-type="bibr"/>-<xref rid="bibr10-1534735419893063" ref-type="bibr">10</xref></sup> while a less diverse bacterial make-up comprised of a small number of species from the <italic>Lactobacillus</italic> genus is considered to be a “healthy” state.<sup><xref rid="bibr38-1534735419893063" ref-type="bibr">38</xref></sup> Therefore, there may be no advantages immunologically of having a diverse array of bacteria in the cervicovaginal milieu.<sup><xref rid="bibr39-1534735419893063" ref-type="bibr">39</xref></sup></p>
              <p>In this study, cervical microbiome was characterized using the PhyloChip, a microarray-based platform that analyzes all 9 variable regions (V1-V9) of the 16S rRNA gene. This capability allows for detection of 16S rRNA sequences that have limited variation in one of their variable regions, whereas high-throughput, next-generation sequencing studies typically only amplify 1 or 2 variable regions (eg, V4, V3-V4). This technology has been previously used to identify differentially abundant microbes in other microbiome studies and results were concordant with V4 sequencing-based analyses.<sup><xref rid="bibr40-1534735419893063" ref-type="bibr">40</xref></sup> Each method has its own limitations as to how its results could accurately represent bacterial composition of the samples being studied. Particular PCR primers used would naturally have stronger binding to certain taxa over others, possibly resulting in overrepresentation or underrepresentation of certain taxa. The use of hybridization signal as outputs used by PhyloChip could possibly contribute to over- and underrepresentations similarly due to the properties of particular probes used. As it would be difficult to characterize the effects due to use of different methodologies, it would be important to use the same methods within and across studies that should be compared.</p>
              <p>It was expected that the cervical microbiome would be a low diversity community. For example, a total of 49 operational taxonomic units (by sequence) were identified in vaginal swab samples from 169 women.<sup><xref rid="bibr41-1534735419893063" ref-type="bibr">41</xref></sup> In this study, a total of 72 to 365 eOTUs were observed per sample, with 1111 eOTUs observed across all samples. Additionally, 27 of these eOTUs were annotated at the strain-level, although they were not statistically significantly different between the nonresponder and responder groups.</p>
              <p>A typical healthy cervicovaginal bacterial community is reported to be composed of a small number of species within genus <italic>Lactobacillus.</italic><sup><xref rid="bibr38-1534735419893063" ref-type="bibr">38</xref></sup> This is believed to be due to production of lactic acid by <italic>Lactobacillus</italic> species leading to protection against genital infections.<sup><xref rid="bibr15-1534735419893063" ref-type="bibr">15</xref>,<xref rid="bibr42-1534735419893063" ref-type="bibr">42</xref><xref rid="bibr43-1534735419893063" ref-type="bibr"/>-<xref rid="bibr44-1534735419893063" ref-type="bibr">44</xref></sup> As would be expected, such <italic>Lactobacillus</italic> dominance was not observed in our study (<xref ref-type="fig" rid="fig2-1534735419893063">Figure 2</xref>), as all but one of the patients were HPV-positive and all had biopsy-proven HSILs.<sup><xref rid="bibr3-1534735419893063" ref-type="bibr">3</xref>,<xref rid="bibr4-1534735419893063" ref-type="bibr">4</xref></sup> Such observation is in line with the findings by others who described that prevalent HPV infection can decrease the abundance of <italic>Lactobacillus</italic> species with a concomitant increase in anaerobes.<sup><xref rid="bibr11-1534735419893063" ref-type="bibr">11</xref></sup> Others have also described that HPV-positive women have different microbial profiles compared with HPV-negative women.<sup><xref rid="bibr12-1534735419893063" ref-type="bibr">12</xref><xref rid="bibr13-1534735419893063" ref-type="bibr"/>-<xref rid="bibr14-1534735419893063" ref-type="bibr">14</xref></sup> The <italic>Lactobacillus</italic> dominance has also been shown to decrease with increased severity of cervical disease.<sup><xref rid="bibr45-1534735419893063" ref-type="bibr">45</xref></sup> Another possible explanation for the differential abundance of <italic>Lactobacillus</italic> species in our study is the fact that <italic>Lactobacillus</italic> dominance has been reported in women of resource-rich settings. In one study, 90% of Caucasian women had <italic>Lactobacillus</italic>-dominant cervicovaginal microbiota. On the other hand, only 80% of Asian and 60% of Hispanic and African American women did.<sup><xref rid="bibr15-1534735419893063" ref-type="bibr">15</xref></sup> In another study of young, healthy South African women, only 37% had <italic>Lactobacillus</italic>-dominant cervicovaginal community.<sup><xref rid="bibr16-1534735419893063" ref-type="bibr">16</xref></sup></p>
              <p>The potential role of race on microbial composition was not only suggested by the differential abundance of <italic>Lactobacillus</italic> species in this study (as discussed above), but also by significant difference in beta diversity based on race (<xref rid="table2-1534735419893063" ref-type="table">Table 2</xref>). Indeed, significant differences in relative abundance of 498 eOTUs were found based on race (<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1534735419893063">Supplementary Table 1</ext-link>). However, there was no difference in racial distribution between the responders and nonresponders (<xref rid="table1-1534735419893063" ref-type="table">Table 1</xref>), suggesting that, while race does influence the composition of cervical microbiome, it does not have effect on vaccine response.</p>
              <p>Significant differences in beta diversity were also observed between HPV 16-positive and HPV 16-negative samples with 15 eOTUs being significantly different in abundance (<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1534735419893063">Supplementary Table 2</ext-link>). Varied abundance in bacterial composition in women infected with HPV 16, 52, or 58 has been reported previously,<sup><xref rid="bibr46-1534735419893063" ref-type="bibr">46</xref></sup> suggesting the possibility that we may be seeing effects between viruses and bacteria. It could be that viral infections have strain-specific effects on bacterial communities. Alternatively, bacterial communities may possibly shape the risk of acquiring or have influence on durations of strain-specific viral infections. As the 2 biotypes revealed using Fast Unifrac significantly separate on the basis of HPV 16 status and race, the influences of these factors on cervical microbiome warrant further investigations (<xref ref-type="fig" rid="fig6-1534735419893063">Figure 6A</xref>).</p>
            </sec>
            <sec sec-type="conclusions" id="section9-1534735419893063">
              <title>Conclusions</title>
              <p>It may be possible for some bacterial taxa such as <italic>Caldithrix, Nitrospirae</italic>, and <italic>Prevotella</italic> to influence the response to HPV therapeutic vaccine. However, similar analyses would need to be repeated with a larger sample size to obtain additional data. The ongoing Phase II clinical trial (NCT02481414) would provide such opportunity. It is possible that the observed cervical microbiome composition associated with nonresponsiveness may be a marker for some underlying immune phenotypes. In other words, the observed possible association could reflect a shared cause rather than a direct causal relationship. In this study, we did not observe an effect of vaccination on the composition of the cervical microbiome. Furthermore, race and infection with HPV 16 appear to influence the beta diversity of cervical microbiome. The major limitation of this study was the small sample size, which is not unexpected given that the clinical trial was in Phase I. Recently, Ilhan and colleagues<sup><xref rid="bibr47-1534735419893063" ref-type="bibr">47</xref></sup> reported a study in which they examined the interplay among microbiota, HPV, and cervical disease status using cervicovaginal metabolic profiling. Non–<italic>Lactobacillus</italic>-dominant communities, particularly in patients with HSILs, showed altered amino acid and nucleotide metabolisms. Future studies should not only be performed with a larger sample size, but should also probe the mechanisms underlying the association of cervical bacterial communities with vaccine nonresponsiveness using such metabolic profiling. If the role of certain bacterial taxa and their associated metabolites with vaccine nonresponsiveness were to be confirmed, it may be worthwhile to consider modulating the cervical microbiome to enhance vaccine efficacy in the future.</p>
            </sec>
            <sec sec-type="supplementary-material" id="section10-1534735419893063" specific-use="figshare">
              <title>Supplemental Material</title>
              <supplementary-material content-type="local-data" id="suppl1-1534735419893063">
                <caption>
                  <title>Supplementary_Table_1_071918 – Supplemental material for Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion</title>
                </caption>
                <media xlink:href="Supplementary_Table_1_071918.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
                <p>Supplemental material, Supplementary_Table_1_071918 for Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion by Rahul Ravilla, Hannah N. Coleman, Cheryl-Emiliane Chow, Luisa Chan, Barbara J. Fuhrman, William W. Greenfield, Michael Scott Robeson, Kathryn Iverson, Horace Spencer and Mayumi Nakagawa in Integrative Cancer Therapies</p>
              </supplementary-material>
            </sec>
            <sec sec-type="supplementary-material" id="section11-1534735419893063" specific-use="figshare">
              <title>Supplemental Material</title>
              <supplementary-material content-type="local-data" id="suppl2-1534735419893063">
                <caption>
                  <title>Supplementary_Table_2_071918 – Supplemental material for Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion</title>
                </caption>
                <media xlink:href="Supplementary_Table_2_071918.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
                <p>Supplemental material, Supplementary_Table_2_071918 for Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion by Rahul Ravilla, Hannah N. Coleman, Cheryl-Emiliane Chow, Luisa Chan, Barbara J. Fuhrman, William W. Greenfield, Michael Scott Robeson, Kathryn Iverson, Horace Spencer and Mayumi Nakagawa in Integrative Cancer Therapies</p>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Authors’ Note:</bold> This work was partly presented at the 2018 American Society for Clinical Oncologists Annual Meeting held in Chicago, IL, in June 2018.</p>
                <p>The data in the form of (1) raw CEL files, (2) a csv file with the rank-normalized HybScore and taxonomic classification per eOTU, and (3) a short readme file are publicly available under the study name “<ext-link ext-link-type="uri" xlink:href="http://UAMS_MNakagawa_2019_IntgCancTher.tgz">UAMS_MNakagawa_2019_IntgCancTher.tgz</ext-link>” within the Phylochip datasets available at <ext-link ext-link-type="uri" xlink:href="https://greengenes.secondgenome.com/">https://greengenes.secondgenome.com/</ext-link>.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Declaration of Conflicting Interests:</bold> The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Mayumi Nakagawa is one of the inventors named in a patent titled “Human Papilloma Virus Therapeutic Vaccine.” Cheryl-Emiliane Chow and Kathryn Iverson are employed by Second Genome, Inc, and hold stock options in the company. Luisa Chan is an employee of Thermo Fisher Scientific, and is a former employee of Second Genome, Inc. She also holds stock options in the latter company.</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a grant from the National Institutes of Health, Grant R01 CA143130.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>ORCID iDs:</bold> Michael Scott Robeson <inline-graphic xlink:href="10.1177_1534735419893063-img1.jpg"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0001-7119-6301">https://orcid.org/0000-0001-7119-6301</ext-link></p>
                <p>Mayumi Nakagawa <inline-graphic xlink:href="10.1177_1534735419893063-img1.jpg"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-0377-4613">https://orcid.org/0000-0002-0377-4613</ext-link></p>
              </fn>
              <fn fn-type="supplementary-material">
                <p><bold>Supplemental Material:</bold> Supplemental material for this article is available online.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="bibr1-1534735419893063">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiffman</surname><given-names>M</given-names></name><name><surname>Doorbar</surname><given-names>J</given-names></name><name><surname>Wentzensen</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal><article-title>Carcinogenic human papillomavirus infection</article-title>. <source>Nat Rev Dis Primers</source>. <year>2016</year>;<volume>2</volume>:<fpage>16086</fpage>.<pub-id pub-id-type="pmid">27905473</pub-id></mixed-citation>
              </ref>
              <ref id="bibr2-1534735419893063">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruinsma</surname><given-names>FJ</given-names></name><name><surname>Quinn</surname><given-names>MA.</given-names></name></person-group><article-title>The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis</article-title>. <source>BJOG</source>. <year>2011</year>;<volume>118</volume>:<fpage>1031</fpage>-<lpage>1041</lpage>.<pub-id pub-id-type="pmid">21449928</pub-id></mixed-citation>
              </ref>
              <ref id="bibr3-1534735419893063">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>HN</given-names></name><name><surname>Greenfield</surname><given-names>WW</given-names></name><name><surname>Stratton</surname><given-names>SL</given-names></name></person-group>, <etal>et al</etal><article-title>Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination</article-title>. <source>Cancer Immunol Immunother</source>. <year>2016</year>;<volume>65</volume>:<fpage>563</fpage>-<lpage>573</lpage>.<pub-id pub-id-type="pmid">26980480</pub-id></mixed-citation>
              </ref>
              <ref id="bibr4-1534735419893063">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenfield</surname><given-names>WW</given-names></name><name><surname>Stratton</surname><given-names>SL</given-names></name><name><surname>Myrick</surname><given-names>RS</given-names></name></person-group>, <etal>et al</etal><article-title>A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3</article-title>. <source>Oncoimmunology</source>. <year>2015</year>;<volume>4</volume>:<fpage>e1031439</fpage>.<pub-id pub-id-type="pmid">26451301</pub-id></mixed-citation>
              </ref>
              <ref id="bibr5-1534735419893063">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gopalakrishnan</surname><given-names>V</given-names></name><name><surname>Spencer</surname><given-names>CN</given-names></name><name><surname>Nezi</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal><article-title>Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients</article-title>. <source>Science</source>. <year>2018</year>;<volume>359</volume>:<fpage>97</fpage>-<lpage>103</lpage>.<pub-id pub-id-type="pmid">29097493</pub-id></mixed-citation>
              </ref>
              <ref id="bibr6-1534735419893063">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matson</surname><given-names>V</given-names></name><name><surname>Fessler</surname><given-names>J</given-names></name><name><surname>Bao</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal><article-title>The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients</article-title>. <source>Science</source>. <year>2018</year>;<volume>359</volume>:<fpage>104</fpage>-<lpage>108</lpage>.<pub-id pub-id-type="pmid">29302014</pub-id></mixed-citation>
              </ref>
              <ref id="bibr7-1534735419893063">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Routy</surname><given-names>B</given-names></name><name><surname>Le Chatelier</surname><given-names>E</given-names></name><name><surname>Derosa</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal><article-title>Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors</article-title>. <source>Science</source>. <year>2018</year>;<volume>359</volume>:<fpage>91</fpage>-<lpage>97</lpage>.<pub-id pub-id-type="pmid">29097494</pub-id></mixed-citation>
              </ref>
              <ref id="bibr8-1534735419893063">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernicker</surname><given-names>EH</given-names></name><name><surname>Quigley</surname><given-names>EMM</given-names></name></person-group><article-title>The gut microbiome influences responses to programmed death 1 therapy in Chinese lung cancer patients—the benefits of diversity</article-title>. <source>J Thorac Oncol</source>. <year>2019</year>;<volume>14</volume>:<fpage>1319</fpage>-<lpage>1322</lpage>.<pub-id pub-id-type="pmid">31345329</pub-id></mixed-citation>
              </ref>
              <ref id="bibr9-1534735419893063">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal><article-title>The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC</article-title>. <source>J Thorac Oncol</source>. <year>2019</year>;<volume>14</volume>:<fpage>1378</fpage>-<lpage>1389</lpage>.<pub-id pub-id-type="pmid">31026576</pub-id></mixed-citation>
              </ref>
              <ref id="bibr10-1534735419893063">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Tu</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal><article-title>Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma</article-title>. <source>J Immunother Cancer</source>. <year>2019</year>;<volume>7</volume>:<fpage>193</fpage>.<pub-id pub-id-type="pmid">31337439</pub-id></mixed-citation>
              </ref>
              <ref id="bibr11-1534735419893063">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dareng</surname><given-names>EO</given-names></name><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Famooto</surname><given-names>AO</given-names></name></person-group>, <etal>et al</etal><article-title>Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women</article-title>. <source>Epidemiol Infect</source>. <year>2016</year>;<volume>144</volume>:<fpage>123</fpage>-<lpage>137</lpage>.<pub-id pub-id-type="pmid">26062721</pub-id></mixed-citation>
              </ref>
              <ref id="bibr12-1534735419893063">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Weng</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Comparison of the vaginal microbiota diversity of women with and without human papillomavirus infection: a cross-sectional study</article-title>. <source>BMC Infect Dis</source>. <year>2013</year>;<volume>13</volume>:<fpage>271</fpage>.<pub-id pub-id-type="pmid">23758857</pub-id></mixed-citation>
              </ref>
              <ref id="bibr13-1534735419893063">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal><article-title>Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>:<fpage>e63514</fpage>.<pub-id pub-id-type="pmid">23717441</pub-id></mixed-citation>
              </ref>
              <ref id="bibr14-1534735419893063">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>HY</given-names></name><name><surname>Kim</surname><given-names>BS</given-names></name><name><surname>Seo</surname><given-names>SS</given-names></name></person-group>, <etal>et al</etal><article-title>The association of uterine cervical microbiota with an increased risk for cervical intraepithelial neoplasia in Korea</article-title>. <source>Clin Microbiol Infect</source>. <year>2015</year>;<volume>21</volume>:674.e1-e9.</mixed-citation>
              </ref>
              <ref id="bibr15-1534735419893063">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravel</surname><given-names>J</given-names></name><name><surname>Gajer</surname><given-names>P</given-names></name><name><surname>Abdo</surname><given-names>Z</given-names></name></person-group>, <etal>et al</etal><article-title>Vaginal microbiome of reproductive-age women</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2011</year>;<volume>108</volume>(<issue>suppl 1</issue>):<fpage>4680</fpage>-<lpage>4687</lpage>.<pub-id pub-id-type="pmid">20534435</pub-id></mixed-citation>
              </ref>
              <ref id="bibr16-1534735419893063">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anahtar</surname><given-names>MN</given-names></name><name><surname>Byrne</surname><given-names>EH</given-names></name><name><surname>Doherty</surname><given-names>KE</given-names></name></person-group>, <etal>et al</etal><article-title>Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract</article-title>. <source>Immunity</source>. <year>2015</year>;<volume>42</volume>:<fpage>965</fpage>-<lpage>976</lpage>.<pub-id pub-id-type="pmid">25992865</pub-id></mixed-citation>
              </ref>
              <ref id="bibr17-1534735419893063">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Coleman</surname><given-names>HN</given-names></name><name><surname>Nagarajan</surname><given-names>U</given-names></name><name><surname>Spencer</surname><given-names>HJ</given-names></name><name><surname>Nakagawa</surname><given-names>M.</given-names></name></person-group><article-title>Candida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine</article-title>. <source>Vaccine</source>. <year>2013</year>;<volume>31</volume>:<fpage>5806</fpage>-<lpage>5813</lpage>.<pub-id pub-id-type="pmid">24135577</pub-id></mixed-citation>
              </ref>
              <ref id="bibr18-1534735419893063">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Horn</surname><given-names>TD</given-names></name><name><surname>Pharis</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal><article-title>Phase 1 clinical trial of intralesional injection of candida antigen for the treatment of warts</article-title>. <source>Arch Dermatol</source>. <year>2010</year>;<volume>146</volume>:<fpage>1431</fpage>-<lpage>1433</lpage>.<pub-id pub-id-type="pmid">21173332</pub-id></mixed-citation>
              </ref>
              <ref id="bibr19-1534735419893063">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeSantis</surname><given-names>TZ</given-names></name><name><surname>Hugenholtz</surname><given-names>P</given-names></name><name><surname>Larsen</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal><article-title>Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB</article-title>. <source>Appl Environ Microbiol</source>. <year>2006</year>;<volume>72</volume>:<fpage>5069</fpage>-<lpage>5072</lpage>.<pub-id pub-id-type="pmid">16820507</pub-id></mixed-citation>
              </ref>
              <ref id="bibr20-1534735419893063">
                <label>20</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Probst</surname><given-names>AJ</given-names></name><name><surname>Lum</surname><given-names>PY</given-names></name><name><surname>John</surname><given-names>B</given-names></name></person-group>, <etal>et al</etal><article-title>Microarray of 16S rRNA gene probes for quantifying population differences across microbiome samples</article-title>. In: <person-group person-group-type="editor"><name><surname>He</surname><given-names>Z</given-names></name></person-group> ed. <source>Microarrays: Current Technology, Innovations and Applications</source>. <publisher-loc>Poole, England</publisher-loc>: <publisher-name>Caister Academic Press</publisher-name>; <volume>2014</volume>:<fpage>99</fpage>-<lpage>119</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr21-1534735419893063">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazen</surname><given-names>TC</given-names></name><name><surname>Dubinsky</surname><given-names>EA</given-names></name><name><surname>DeSantis</surname><given-names>TZ</given-names></name></person-group>, <etal>et al</etal><article-title>Deep-sea oil plume enriches indigenous oil-degrading bacteria</article-title>. <source>Science</source>. <year>2010</year>;<volume>330</volume>:<fpage>204</fpage>-<lpage>208</lpage>.<pub-id pub-id-type="pmid">20736401</pub-id></mixed-citation>
              </ref>
              <ref id="bibr22-1534735419893063">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>D</given-names></name><name><surname>Price</surname><given-names>MN</given-names></name><name><surname>Goodrich</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal><article-title>An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea</article-title>. <source>ISME J</source>. <year>2012</year>;<volume>6</volume>:<fpage>610</fpage>-<lpage>618</lpage>.<pub-id pub-id-type="pmid">22134646</pub-id></mixed-citation>
              </ref>
              <ref id="bibr23-1534735419893063">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faith</surname><given-names>DP.</given-names></name></person-group><article-title>Conservation evaluation and phylogenetic diversity</article-title>. <source>Biol Conserv</source>. <year>1992</year>;<volume>61</volume>:<fpage>1</fpage>-<lpage>10</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr24-1534735419893063">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soberon</surname><given-names>JM</given-names></name><name><surname>Llorente</surname><given-names>JB.</given-names></name></person-group><article-title>The use of species accumulation functions for the prediction of species richness</article-title>. <source>Conserv Biol</source>. <year>1993</year>;<volume>7</volume>:<fpage>480</fpage>-<lpage>488</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr25-1534735419893063">
                <label>25</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Magurran</surname><given-names>AE.</given-names></name></person-group><source>Measuring Biological Diversity</source>. <publisher-loc>Oxford, England</publisher-loc>: <publisher-name>Blackwell</publisher-name>; <year>2004</year>.</mixed-citation>
              </ref>
              <ref id="bibr26-1534735419893063">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>JR</given-names></name><name><surname>Curtis</surname><given-names>JT.</given-names></name></person-group><article-title>An ordination of the upland forest communities of Southern Wisconsin</article-title>. <source>Ecol Monogr</source>. <year>1957</year>;<volume>27</volume>:<fpage>325</fpage>-<lpage>349</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr27-1534735419893063">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaccard</surname><given-names>P.</given-names></name></person-group><article-title>The distribution of the flora in the alpine zone</article-title>. <source>New Phytol</source>. <year>1912</year>;<volume>11</volume>:<fpage>37</fpage>-<lpage>50</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr28-1534735419893063">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>MJ.</given-names></name></person-group><article-title>A new method for non-parametric multivariate analysis of variance</article-title>. <source>Austral Ecol</source>. <year>2001</year>;<volume>26</volume>:<fpage>32</fpage>-<lpage>46</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr29-1534735419893063">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arumugam</surname><given-names>M</given-names></name><name><surname>Raes</surname><given-names>J</given-names></name><name><surname>Pelletier</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal><article-title>Enterotypes of the human gut microbiome</article-title>. <source>Nature</source>. <year>2011</year>;<volume>473</volume>:<fpage>174</fpage>-<lpage>180</lpage>.<pub-id pub-id-type="pmid">21508958</pub-id></mixed-citation>
              </ref>
              <ref id="bibr30-1534735419893063">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamady</surname><given-names>M</given-names></name><name><surname>Lozupone</surname><given-names>C</given-names></name><name><surname>Knight</surname><given-names>R.</given-names></name></person-group><article-title>Fast UniFrac: facilitating high-throughput phylogenetic analyses of microbial communities including analysis of pyrosequencing and PhyloChip data</article-title>. <source>ISME J</source>. <year>2010</year>;<volume>4</volume>:<fpage>17</fpage>-<lpage>27</lpage>.<pub-id pub-id-type="pmid">19710709</pub-id></mixed-citation>
              </ref>
              <ref id="bibr31-1534735419893063">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>Y</given-names></name><name><surname>Benjamini</surname><given-names>Y.</given-names></name></person-group><article-title>More powerful procedures for multiple significance testing</article-title>. <source>Stat Med</source>. <year>1990</year>;<volume>9</volume>:<fpage>811</fpage>-<lpage>818</lpage>.<pub-id pub-id-type="pmid">2218183</pub-id></mixed-citation>
              </ref>
              <ref id="bibr32-1534735419893063">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>YE</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal><article-title>Homogeneity of the vaginal microbiome at the cervix, posterior fornix, and vaginal canal in pregnant Chinese women</article-title>. <source>Microb Ecol</source>. <year>2015</year>;<volume>69</volume>:<fpage>407</fpage>-<lpage>414</lpage>.<pub-id pub-id-type="pmid">25230887</pub-id></mixed-citation>
              </ref>
              <ref id="bibr33-1534735419893063">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>JM.</given-names></name></person-group><article-title>The immune response to <italic>Prevotella</italic> bacteria in chronic inflammatory disease</article-title>. <source>Immunology</source>. <year>2017</year>;<volume>151</volume>:<fpage>363</fpage>-<lpage>374</lpage>.<pub-id pub-id-type="pmid">28542929</pub-id></mixed-citation>
              </ref>
              <ref id="bibr34-1534735419893063">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Si</surname><given-names>J</given-names></name><name><surname>You</surname><given-names>HJ</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Sung</surname><given-names>J</given-names></name><name><surname>Ko</surname><given-names>G.</given-names></name></person-group><article-title><italic>Prevotella</italic> as a hub for vaginal microbiota under the influence of host genetics and their association with obesity</article-title>. <source>Cell Host Microbe</source>. <year>2017</year>;<volume>21</volume>:<fpage>97</fpage>-<lpage>105</lpage>.<pub-id pub-id-type="pmid">28017660</pub-id></mixed-citation>
              </ref>
              <ref id="bibr35-1534735419893063">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onderdonk</surname><given-names>AB</given-names></name><name><surname>Delaney</surname><given-names>ML</given-names></name><name><surname>Fichorova</surname><given-names>RN.</given-names></name></person-group><article-title>The human microbiome during bacterial vaginosis</article-title>. <source>Clin Microbiol Rev</source>. <year>2016</year>;<volume>29</volume>:<fpage>223</fpage>-<lpage>238</lpage>.<pub-id pub-id-type="pmid">26864580</pub-id></mixed-citation>
              </ref>
              <ref id="bibr36-1534735419893063">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miroshnichenko</surname><given-names>ML</given-names></name><name><surname>Kostrikina</surname><given-names>NA</given-names></name><name><surname>Chernyh</surname><given-names>NA</given-names></name></person-group>, <etal>et al</etal><article-title><italic>Caldithrix abyssi</italic> gen nov, sp nov, a nitrate-reducing, thermophilic, anaerobic bacterium isolated from a Mid-Atlantic Ridge hydrothermal vent, represents a novel bacterial lineage</article-title>. <source>Int J Syst Evol Microbiol</source>. <year>2003</year>;<volume>53</volume>(<issue>pt 1</issue>):<fpage>323</fpage>-<lpage>329</lpage>.<pub-id pub-id-type="pmid">12656191</pub-id></mixed-citation>
              </ref>
              <ref id="bibr37-1534735419893063">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philips</surname><given-names>S</given-names></name><name><surname>Laanbroek</surname><given-names>HJ</given-names></name><name><surname>Verstraete</surname><given-names>W.</given-names></name></person-group><article-title>Origin, causes and effects of increased nitrite concentrations in aquatic environments</article-title>. <source>Rev Environ Sci Biol</source>. <year>2002</year>;<volume>1</volume>:<fpage>115</fpage>-<lpage>141</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr38-1534735419893063">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anahtar</surname><given-names>MN</given-names></name><name><surname>Gootenberg</surname><given-names>DB</given-names></name><name><surname>Mitchell</surname><given-names>CM</given-names></name><name><surname>Kwon</surname><given-names>DS.</given-names></name></person-group><article-title>Cervicovaginal microbiota and -reproductive health: the virtue of simplicity</article-title>. <source>Cell Host Microbe</source>. <year>2018</year>;<volume>23</volume>:<fpage>159</fpage>-<lpage>168</lpage>.<pub-id pub-id-type="pmid">29447695</pub-id></mixed-citation>
              </ref>
              <ref id="bibr39-1534735419893063">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shade</surname><given-names>A.</given-names></name></person-group><article-title>Diversity is the question, not the answer</article-title>. <source>ISME J</source>. <year>2017</year>;<volume>11</volume>:<fpage>1</fpage>-<lpage>6</lpage>.<pub-id pub-id-type="pmid">27636395</pub-id></mixed-citation>
              </ref>
              <ref id="bibr40-1534735419893063">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miezeiewski</surname><given-names>M</given-names></name><name><surname>Schnaufer</surname><given-names>T</given-names></name><name><surname>Muravsky</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal><article-title>An in vitro culture model to study the dynamics of colonic microbiota in Syrian golden hamsters and their susceptibility to infection with</article-title><source>Clostridium difficile. ISME J</source>. <year>2015</year>;<volume>9</volume>:<fpage>321</fpage>-<lpage>332</lpage>.<pub-id pub-id-type="pmid">25036923</pub-id></mixed-citation>
              </ref>
              <ref id="bibr41-1534735419893063">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitra</surname><given-names>A</given-names></name><name><surname>MacIntyre</surname><given-names>DA</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name></person-group>, <etal>et al</etal><article-title>Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity</article-title>. <source>Sci Rep</source>. <year>2015</year>;<volume>5</volume>:<fpage>16865</fpage>.<pub-id pub-id-type="pmid">26574055</pub-id></mixed-citation>
              </ref>
              <ref id="bibr42-1534735419893063">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hickey</surname><given-names>RJ</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Pierson</surname><given-names>JD</given-names></name><name><surname>Ravel</surname><given-names>J</given-names></name><name><surname>Forney</surname><given-names>LJ.</given-names></name></person-group><article-title>Understanding vaginal microbiome complexity from an ecological perspective</article-title>. <source>Transl Res</source>. <year>2012</year>;<volume>160</volume>:<fpage>267</fpage>-<lpage>282</lpage>.<pub-id pub-id-type="pmid">22683415</pub-id></mixed-citation>
              </ref>
              <ref id="bibr43-1534735419893063">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>DH</given-names></name><name><surname>Marrazzo</surname><given-names>JM.</given-names></name></person-group><article-title>The vaginal microbiome: current understanding and future directions</article-title>. <source>J Infect Dis</source>. Aug 15 <year>2016</year>;<volume>214</volume>(<issue>suppl 1</issue>):<fpage>S36</fpage>-<lpage>S41</lpage>.<pub-id pub-id-type="pmid">27449871</pub-id></mixed-citation>
              </ref>
              <ref id="bibr44-1534735419893063">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunn</surname><given-names>KL</given-names></name><name><surname>Forney</surname><given-names>LJ.</given-names></name></person-group><article-title>Unraveling the dynamics of the human vaginal microbiome</article-title>. <source>Yale J Biol Med</source>. <year>2016</year>;<volume>89</volume>:<fpage>331</fpage>-<lpage>337</lpage>.<pub-id pub-id-type="pmid">27698617</pub-id></mixed-citation>
              </ref>
              <ref id="bibr45-1534735419893063">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laniewski</surname><given-names>P</given-names></name><name><surname>Barnes</surname><given-names>D</given-names></name><name><surname>Goulder</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal><article-title>Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women</article-title>. <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>:<fpage>7593</fpage>.<pub-id pub-id-type="pmid">29765068</pub-id></mixed-citation>
              </ref>
              <ref id="bibr46-1534735419893063">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Wan</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name></person-group><article-title>Cervicovaginal microbiota composition correlates with the acquisition of high-risk human papillomavirus types</article-title>. <source>Int J Cancer</source>. <year>2018</year>;<volume>43</volume>:<fpage>621</fpage>-<lpage>634</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr47-1534735419893063">
                <label>47</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ilhan</surname><given-names>ZE</given-names></name><name><surname>Laniewski</surname><given-names>P</given-names></name><name><surname>Thomas</surname><given-names>N</given-names></name><name><surname>Roe</surname><given-names>DJ</given-names></name><name><surname>Chase</surname><given-names>DM</given-names></name><name><surname>Herbst-Kralovetz</surname><given-names>MM.</given-names></name></person-group><article-title>Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling</article-title>. <source>EBioMedicine</source>. <year>2019</year>;<volume>44</volume>:<fpage>675</fpage>-<lpage>690</lpage>.<pub-id pub-id-type="pmid">31027917</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
